Home News About Us Contact Contributors Disclaimer Privacy Policy Help FAQ

Home
Search
Quick Search
Advanced
Fulltext
Browse
Collections
Persons
My eDoc
Session History
Login
Name:
Password:
Documentation
Help
Support Wiki
Direct access to
document ID:


          Institute: MPI für molekulare Genetik     Collection: Department of Vertebrate Genomics     Display Documents



  history
ID: 230823.0, MPI für molekulare Genetik / Department of Vertebrate Genomics
A customized monocyte cDNA microarray for diagnosis of rheumatoid arthritis and prognosis of anti-TNF-α therapy
Authors:Stuhlmüller, B.; Tandon, N.; Hultschig, C.; Kuban, R. J.; Hernandez, M.; Burmester, G. R.; Häupl, T.
Language:English
Date of Publication (YYYY-MM-DD):2004-02-24
Title of Journal:Arthritis Research & Therapy
Journal Abbrev.:Arthritis Res Ther
Volume:6
Issue / Number:Suppl. 1
Start Page:69
End Page:69
Copyright:© 1999-2005 BioMed Central Ltd
Review Status:not specified
Audience:Experts Only
Abstract / Description:Background
In rheumatoid arthritis (RA) macrophages (Mf) play a pivotal role. They become highly activated in synovitis and at the cartilage–pannus junction. Furthermore, therapeutic neutralization of molecules produced by activated Mf lead to clinical improvement in RA, and circulating monocytes (MO) of the peripheral blood in patients with RA spontaneously express proinflammatory genes (IL-1β, IL-6, TNF).

Methods
A custom RA-MO cDNA microarray was generated using differentially expressed genes obtained from gene subtraction and from comparative whole genome wide U133A analysis in normal donors, active and anti-TNF-α created RA patients. Genes were selected using MAS 5.0, multtest and PAM. The custom microarray consists of 313 genes including guide dots, and positive (housekeeping genes and spike controls) and negative controls for image and statistical analysis. Each probe was spotted in 16 replicates.

Results
The RA-MO chipset-II was validated using the following: non-stimulated and LPS, PMA, Vit.D3+LPS, PMA+LPS stimulated U937 cells; nonstimulated and LPS stimulated healthy donor MO; MO from normal donors (n = 3) and RA patients before and during anti-TNF-α treatment (n = 5 each); and synovial tissue from normal individuals (n = 2) and RA patients (n = 2). Not only LPS/PMA regulated genes but also RA specific and anti-TNF-α regulated genes were validated. In addition, we could clarify whether these genes are differentially transcribed only in MO or whether they can also be found in RA tissue Mf. Our data indicate a high degree of reproducibility that is sufficient for diagnostic applications and therapy monitoring.

Conclusion
The RA-MO chipset-II microarray is competitive and flexible for enlargement of the number of genes. The current gene selection will contribute to validating the role of monocytes in disease activity, to therapeutic interventions, and may improve the knowledge on the regulation of pathways in activated monocytes in chronic inflammation.
Comment of the Author/Creator:from 24th European Workshop for Rheumatology Research
Berlin, Germany, 26–29 February 2004
External Publication Status:published
Document Type:Article
Communicated by:Hans Lehrach
Affiliations:MPI für molekulare Genetik
External Affiliations:Charité, Department of Rheumatology, MPI-MG, Berlin, Germany
Identifiers:ISSN:1478-6354
DOI:10.1186/ar1111
The scope and number of records on eDoc is subject to the collection policies defined by each institute - see "info" button in the collection browse view.